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Aims The subcutaneous implantable cardioverter defibrillator (S-ICD) was introduced to overcome complications related to
transvenous leads. Adoption of the S-ICD requires implanters to learn a new implantation technique. The aim of this
study was to assess the learning curve for S-ICD implanters with respect to implant-related complications, procedure
time, and inappropriate shocks (IASs).
Methods and
results
In a pooled cohort from two clinical S-ICD databases, the IDE Trial and the EFFORTLESS Registry, complications, IASs
at 180 days follow-up and implant procedure duration were assessed. Patients were grouped in quartiles based on
experience of the implanter and Kaplan–Meier estimates of complication and IAS rates were calculated. A total of
882 patients implanted in 61 centres by 107 implanters with a median of 4 implants (IQR 1,8) were analysed. There
were a total of 59 patients with complications and 48 patients with IAS. The complication rate decreased significantly
from 9.8% in Quartile 1 (least experience) to 5.4% in Quartile 4 (most experience) (P ¼ 0.02) and non-significantly for
IAS from 7.9 to 4.8% (P ¼ 0.10). Multivariable analysis demonstrated a hazard ratio of 0.78 (P ¼ 0.045) for complica-
tions and 1.01 (P ¼ 0.958) for IAS. Dual-zone programming increased with experience of the individual implanter
(P, 0.001), which reduced IAS significantly in the multivariable model (HR 0.44, P ¼ 0.01). Procedure time decreased
from 75 to 65 min (P, 0.001). The complication rate and procedure time stabilized after Quartile 2 (.13 implants).
Conclusion There is a short and significant learning curve associated with physicians adopting the S-ICD. Performance stabilizes
after 13 implants.
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Introduction
The subcutaneous implantable cardioverter defibrillator (S-ICD)
was introduced to overcome complications related to transvenous
leads. The available evidence from S-ICD studies shows a complica-
tion rate similar to transvenous implantable cardioverter defibrilla-
tor (ICD) therapy but includes the learning curve of Physicians
becoming familiar with this new technology.1–3
It is widely accepted that increasing experience improves per-
formance, particularly when adopting a new procedure. The intro-
duction of the S-ICD required implanting physicians to adopt a new
implant technique and different modes of ICD programming.4,5 The
pulse generator of the S-ICD is positioned in the left lateral axillary
line on the chest wall and uses a subcutaneous sensing and defibril-
lation lead, whereas conventional transvenous ICDs use endocardial
leads. The S-ICD requires more energy for defibrillation, which in-
creases the size of the pulse generator. Tunnelling the lead in this
new position and larger size of the pulse generator and pocket
require a different surgical approach than for transvenous implants.
The association between operator experience and the impact on
adverse events is well documented.6 For cardiovascular procedures,
operator training and volume have been associated with patient
outcomes, including mortality in percutaneous coronary interven-
tion procedures and infection and mechanical complications in
transvenous ICD implants and replacements.7– 9 Olde Nordkamp
et al. observed more inappropriate shocks (IASs) and complications
in initial experience per implanting centre compared with later
experience in a Dutch S-ICD cohort.10
The aim of this study was to assess the learning curve for individ-
ual S-ICD implanters with respect to implant-related complications,
procedure time, and IASs.We hypothesized the presence of a learn-
ing curve with the introduction of the S-ICD. Therefore, complica-
tions, implant procedure duration, and IASs were expected to
decrease with increasing experience of the implanter, with stabiliza-
tion after a given learning interval.
Methods
Study cohort
The design of this pooled cohort has been described in detail elsewhere,
but briefly: the pooled cohort consists of a total of 889 patients, 568
patients from the EFFORTLESS registry (NCT01085435), 308 from
the IDE study (NCT01064076), and 13 patients who were in both stud-
ies.1,11,12 Data were collected until 12 November 2013 for the ongoing
EFFORTLESS registry. The IDE study follow-up ended on 14 February
2012. Participation in both studies complied with the Helsinki declar-
ation and required approval of local ethics or institutional review boards
and informed consent. The device programming, including the use of the
morphology-based discrimination algorithm, was at the physicians’
discretion.
Endpoints
Endpoints included in the analysis were complications, procedure time,
and IASs. Complications were defined as those related to the implant
procedure and required surgical intervention. Complications unrelated
to the implant procedure that did require a surgical intervention
were excluded (inability to communicate with the device n ¼ 1, IASs
n ¼ 12, and premature battery depletion n ¼ 1). Procedure time was
collected for patients enrolled in the EFFORTLESS registry and was
defined as the time between incision and closure of the wound
(skin-to-skin time). Inappropriate shocks were defined as shocks for
any reason but ventricular tachyarrhythmias. Classification of complica-
tions and treated events were reported by the site, and appropriateness
of therapy or detection was adjudicated by the sponsor (EFFORTLESS)
or Clinical Events Committee (IDE). The complication rate and IAS rate
were assessed by calculating Kaplan–Meier estimates at 180 days
post-implantation.
Experience
Outcomes with S-ICD therapy were analysed for individual implanter
experience: per implanter, all patients were chronologically ranked
and subsequently distributed in quartiles. The first quartile of patients
represents the initial experience of implanters, whereas the last quartile
represents implant procedures when implanters had the most experi-
ence. During the EFFORTLESS study, the device was commercially avail-
able in Europe outside of the study. Therefore, the manufacturer’s
device tracking database was used to adjust the implant ranking for im-
plants done outside of the EFFORTLESS study per individual implanters.
The data presented in this study only represent patients who partici-
pated in the EFFORTLESS or IDE study.
Statistical analysis
The appropriateness of pooling the two studies was assessed by evalu-
ation of the study as a predictor of each endpoint. Descriptive statistics
are reported using the mean+ standard deviation for continuous vari-
ables and numbers with percentages for dichotomous variables unless
otherwise indicated. Differences in baseline characteristics were tested
using a Student’s t-test or ANOVA for parametric numerical variables
and Fisher’s exact test for dichotomous variables unless otherwise indi-
cated. Kaplan–Meier analyses and log-rank test were used to assess
event rates across groups.
Univariable models were fit to assess which patient and programming
characteristics were associated with each of the three endpoints. Cox
proportional hazard models were used for the outcomes of complica-
tions and IASs. A general linear model was fit for the outcome proced-
ure time. Each variable that was significant at the 0.10 level was included
as a candidate for the final multivariable model for each outcome. Back-
ward selection was used in a multivariable Cox proportional hazards
model with a significance level for retention in the model of 0.10. All
statistical analyses were performed using SAS version 9.3 (SAS Institute,
Cary, NC). P values of ,0.05 were deemed statistically significant.
What’s new
† There is a learning curve for physicians adopting the S-ICD.
† The complications rate decreased from 9.8 to 5.4%.
† Performance stabilizes after 13 implants.
† Inappropriate shocks (IASs) decreased during the study due
to higher rates of dual-zone programming but were not re-
lated to physician experience.
† The use of dual-zone programming will help new implanters
achieve low IAS rates.
† Procedure time stabilized at 65 min after 13 implants, which
is similar to dual-chamber transvenous ICD implant
durations.
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Results
Study population
From August 2009 to November 2013, 889 patients were enrolled
in both studies. There was no evidence that endpoints significantly
differed by study (complications P ¼ 0.47, IASs 0.12). Procedure
time was only collected in the EFFORTLESS registry.
Of these 889 patients (73% men, mean age 50+ 17 years), 70%
received an S-ICD for primary prevention and 38% had ischaemic
heart disease. A total of 882 implants were performed in 61 implant-
ing centres by 107 implanters with a median of 4 implants (IQR 1,8).
The remaining seven patients were not implanted. Most implanters
in this cohort performed a total of 4 implants (Quartile 1) and 11
implanters performed more than 28 implants (Quartile 4). Add-
itionally, there were 187 implants outside the EFFORTLESS study
identified in the manufacturer’s device tracking database that were
used to adjust the implant order per individual implanter. The pa-
tient characteristics per quartile of increasing implant experience
are summarized in Table 1.
Complications
Therewere 59 patients with 72 complications at 180 days follow-up.
Of these complications, infections and suboptimal implantation
were most common (Table 2). The median time from implant to
complication was 18 days (mean 45+ 71). The complication rate
decreased almost by half from 9.8 to 5.4% (P ¼ 0.019) over the ex-
perience quartiles (Figure 1). The absolute risk reduction, therefore,
was 4.4% between Quartiles 1 and 4, and the relative risk reduction
was 44.8%. The largest decrease was seen between Q1 and Q2. The
complication rate stabilized in Quartile 3, which represents .13
procedures per implanter and indicates the end of the learning
curve. In a Cox proportional hazard model for complications, in-
creasing experience reduced the occurrence of complications per
quartile (HR 0.78, P ¼ 0.045, Table 3).
In the univariable model, there was a non-significant trend to-
wards fewer complication over the years 2009–2013 (P ¼ 0.07).
However, implant year was not retained in the multivariable model
(Table 3). Implant year also did not interact with physician experi-
ence (Supplementary material online, Figure S1). No individual com-
plication type was observed to drive the decrease in complications
(Supplementary material online, Table S1).
The complication rate in implanter’s first four S-ICD patients for
thosewho ended as relatively high-volume implanters (.5 implants,
50% of implanters) was compared with lower-volume implanters in
the study (1–5 implants, 50% of implanters). Higher-volume implan-
ters had a similar complication rate (9.4%, 95% CI 5.6–15.7%) in the
first four implants to lower-volume implanters (10.2%, 95% CI 5.8–
17.6%, P ¼ 0.429).
Procedure time
A sub-analysis among 434 EFFORTLESS patients for whom
skin-to-skin procedure time was available showed a decrease
from 75+ 34 min in Quartile 1 to 65+ 23 min in Quartile 4
(P, 0.001), which stabilized in Quartiles 3 and 4 (Figure 2). A gen-
eralized linear model for procedure time showed that the decrease
in procedure time did not remain significant (P ¼ 0.81) after adjust-
ment for confounders: implant year, age, congenital heart disease,
and prior ICD (Table 4).
Inappropriate shocks
In this cohort, there were a total of 107 IASs in 48 patients during
the first 180 days. Seventy-one per cent of the IASs were related
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Table 1 Patient characteristics per experience quartile
Characteristic (number of implants) Quartiles
Q1 (1–4) Q2 (5–12) Q3 (13–28) Q4 (>28) P value
Number of patients 248 203 222 216
Implantersa 95 48 25 11
Age (years) 51.0+17.0 47.3+17.9 48.6+16.4 53.9+15.8 ,0.001
Female (%) 62 (25.1) 54 (26.7) 65 (30.2) 60 (28.2) 0.653
Primary prevention (%) 180 (72.9) 135 (67.5) 145 (67.4) 150 (71.1) 0.503
QRS (ms) 107+27 103+21 104+22 108+25 0.224
LVEF (%) 38+17 40+18 42+18 37+17 0.59
BMI 28.5+6.7 28.5+7.2 28.0+6.9 27.9+5.6 0.764
Congestive heart failure (%) 128 (52.0) 80 (40.2) 73 (34.0) 88 (41.3) 0.001
AF (%) 40 (16.3) 23 (11.6) 40 (18.6) 40 (18.8) 0.154
NYHA Classes III and IV (%) 33 (26.8) 21 (28.8) 26 (44.1) 28 (38.9) 0.070
Diabetes (%) 62 (25.2) 25 (12.6) 33 (15.3) 36 (16.9) 0.004
COPD (%) 18 (7.3) 4 (2.0) 21 (9.8) 13 (6.1) 0.007
Hypertension (%) 129 (52.4) 70 (35.4) 71 (33.0) 61 (28.6) ,0.001
Dual-zone programming (%) 152 (64.1) 154 (79.0) 176 (83.4) 207 (95.8) ,0.001
Conditional zone rate 195+20 201+20 201+21 195+14 0.79
LVEF, left ventricular ejection fraction; BMI, body mass index; CHF, congestive heart failure; HCM, hypertrophic cardiomyopathy; AF, atrial fibrillation; NYHA, New York Heart
Association classification; COPD, chronic obstructive pulmonary disease.
aImplanters can contribute to more than one quartile.
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to cardiac oversensing, 19% to supraventricular tachycardias, and
10% to non-cardiac oversensing. The median time between implant
and the occurrence of the first IAS was 98 days (141+105). There
was a non-significant trend towards fewer IASs from 7.9 to 4.5%
from Quartile 1 to Quartile 4 (P ¼ 0.10) (Figure 3). Dual-zone pro-
gramming increased significantly over the experience quartiles from
64 to 96% (P, 0.001). In a Cox proportional hazardmodel for IASs,
increasing experience was not found to be a predictor for the de-
crease of IASs (HR 1.01, P ¼ 0.96) (Table 5). However, dual-zone
programming was significantly associated with fewer IASs (HR
0.44, P ¼ 0.01).
Discussion
Main findings
This study describes the learning curve for individual S-ICD implanters
in the two largest cohorts to date regarding implant-related complica-
tions, procedure duration, and IASs. The main finding of this study is
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Table 2 Complications in the first 6 months
Description Number
of events
System infection 16
Electrode movement 7
Suboptimal electrode position 7
Erosion 5
Discomfort 4
Haematoma 4
Suboptimal pulse generator and electrode position 4
Adverse reaction to medication 3
Inadequate/prolonged healing of incision site 3
Incision/superficial infection 3
Pulse generator movement/revision 3
Suboptimal pulse generator position 2
Failed defibrillation threshold test 2
Acute hypoxic respiratory failure 1
Incomplete electrode connection to the device 1
Near syncope/dizziness/shortness of breath/confusion 1
Pleural effusion 1
Pneumothorax 1
Seroma 1
Suspected worsening of ischaemia 1
Suture discomfort 1
Undersensing 1
Grand total 72
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Figure 1 Kaplan–Meier analysis of experience quartiles and
complications at 180 days. Q1: Experience Quartile 1 (implants
1–4); Q2: Experience Quartile 2 (implants 5–12); Q3: Experience
Quartile 3 (implants 13–28); Q4: Experience Quartile 4 (implants
.28); ARR, absolute risk reduction; RRR, relative risk reduction.
P value is Kaplan–Meier trend test.
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Table 3 Multivariable Cox proportional hazard model
for complications
Characteristic Hazard ratio
(95% CI)
P value
Physician experience (per quartile) 0.78 (0.61, 0.99) 0.045
BMI (per 5 units) 1.15 (0.98, 1.34) 0.090
Age (per 5 years) 0.89 (0.82, 0.96) 0.005
Atrial fibrillation (yes vs. no) 1.91 (1.00, 3.67) 0.051
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Figure 2 Skin-to-skin procedure time by experience quartiles.
Q1: Experience Quartile 1 (implants 1–4); Q2: Experience Quar-
tile 2 (implants 5–12); Q3: Experience Quartile 3 (implants 13–
28); Q4: Experience Quartile 4 (implants .28). Solid line is
mean, and dashed lines are +1 SD. P value is trend test.
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Table 4 Generalized linear model for procedure time
Characteristic Effect (95% CI) P value
Intercept 101.2 (91.1, 111.3) ,0.001
Physician quartile (per quartile) 0.3 (22.4, 3.1) 0.807
Implant year (per year starting
in 2009)
26.7 (29.2, 24.1) ,0.001
Age (per 5 years) 21.7 (22.4, 21.0) ,0.001
Congenital disease (yes vs. no) 26.1 (8.3, 43.9) 0.004
Prior ICD (yes vs. no) 8.9 (2.0, 15.8) 0.011
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that implant-related complications significantly decrease from 9.8 to
5.4% with increasing experience of the individual implanter, and stabi-
lized in Quartile 3, which represents .13 procedures per implanter.
The unadjusted procedure duration decreased over the experience
quartiles, but it did not remain significant after multivariable adjust-
ment for baseline characteristics. There was a non-significant decrease
of IASs over the experience quartiles, which was primarily explained
by the increase in dual-zone programming of the S-ICD.
Complications
The complication rate decreased almost by half when the earliest
experience (Quartile 1: first four procedures per implanter) was
compared with the latest experience in this cohort. The largest re-
duction was seen between Q1 and Q2, indicating that most of the
learning happens in the implanter’s first four cases. It is possible that
this result was driven by individual physicians who had a low com-
plication rate in their early experience vs. implanters that may have
experienced a higher complication rate early and stopped implant-
ing. To explore whether this effect was driven by individual physi-
cians, the complication rate in the first four implants per individual
implanter was assessed.
High-volume implanters had a similar complication rate in the first
four implants as those who implanted fewer S-ICDs. This indicates
that the complication rate during the earliest experience is similar
for all implanters, and individual physicians who became high-
volume implanters did not have a lower complication rate in their
early experience. If the low-volume implanter would have continued
to increase their experience, they may reduce their complication
rate to the level of high-volume implanters.
In the 2-year follow-up of the combined EFFORTLESS and
IDE study, which included the earliest commercial and investiga-
tional experiences, Burke et al. found a complication rate of 7.7%
at 180 days.1 That study showed that the complication rate re-
duced over time. In the current study with the same cohort,
the difference in implant period did not remain significant in
the multivariable model, whereas experience of the implanters
did. Therefore, this analysis of the same cohort indicates that
the complication rate of 7.7% was elevated by the early learning
curve of individual implanters and that the rate for experienced
implanters is lower.
Procedure time
The procedure time decreased significantly from 75+34 to 65+
23 min over the experience quartiles in the unadjusted analysis
(Figure 2). Interestingly, in the multivariable model, each increase in
experience quartile did not significantly reduce procedure time, but
each increment in implant year did. This indicates that the implant
procedure has become more efficient over time, such as by the
introduction of the two-incision technique that omits the superior
parasternal incision.13 In the unadjusted analysis, the procedure
time increased in the second quartile to 78 min compared with
75 the first quartile, which may be explained by the presence of a
proctor during implants in Q1. In the presumed implants without a
proctor (Q2–Q4), the trend of reduction in procedure time reduc-
tion is clearer. When procedure time in Quartile 4 is compared with
unpublished data from MADIT-CRT, it is longer than in single-
chamber ICDs, 65+ 23 vs. 51+ 25 min, respectively (P, 0.001),
and similar to dual-chamber ICDs 63+30 min (P ¼ 0.414).14
Inappropriate shocks
There was a non-significant trend towards fewer IASs with increas-
ing experience of the individual implanter. In the multivariable mod-
el, this trend was caused by increased dual-zone programming over
the experience quartiles. The discrimination algorithm in the condi-
tional zone between 170 and 250 beats per minutes has proved to
be equally good at detecting ventricular arrhythmias and superior
with respect to discrimination of supraventricular arrhythmia in a
head-to-head comparison study published in 2012.5 Roughly half
of the cohort of this study was implanted prior to this publication,
which may explain the increase in dual-zone programming. The in-
creased use of dual-zone programming can be considered as learn-
ing at a global level enabling knowledge to be transferred to new
implanters. Potential other confounders such as discrimination algo-
rithm improvements and reduction of myopotential oversensing
after introduction of the suture sleeve may have contributed, but
these variables were not collected in both studies. Improvement
of the discrimination algorithm may continue to reduce the IAS
shock rate but need to be proved in prospective studies.15 Future
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Table 5 Multivariable Cox proportional hazard model
for IASs
Characteristic Hazard ratio
(95% CI)
P value
Physician quartile (per quartile) 1.01 (0.77, 1.32) 0.958
Age (per 5 years) 0.91 (0.83, 0.99) 0.028
Programming zones (dual vs. single) 0.44 (0.24, 0.82) 0.010
NYHA class (II– IV vs. I) 2.09 (1.13, 3.88) 0.020
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Figure 3 Kaplan–Meier analysis of experience quartiles and
IASs at 180 days. Q1: Experience Quartile 1 (implants 1–4); Q2:
Experience Quartile 2 (implants 5–12); Q3: Experience Quartile
3 (implants 13–28); Q4: Experience Quartile 4 (implants .28);
ARR, absolute risk reduction; RRR, relative risk reduction. P value
is Kaplan–Meier trend test.
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studies into programming of rate cut-off values for the conditional
and unconditional zones are warranted in order to optimize sensi-
tivity and specificity of the detection of ventricular arrhythmias.
Clinical implications
This study has several implications for training and instruction of
new S-ICD implanters. First, we observed rapid improved perform-
ance by implanters resulting in a stable complication rate after 13 im-
plants. The complication rate decreased for all implanters after four
implants. Complications occurring during the early experience
should encourage the implanter to analyse and adjust the workflow
where needed and continue the learning process. Interruption of
implants in response to complications stops the learning process
and diminishes the impact of skills acquired up to that point.
There was no individual implanters learning curve with respect to
IASs and procedure time. Strategies to reduce IASs can be trans-
ferred to new implanters.16,17 Therefore, the IAS rate in Quartile
4 in this analysis is achievable for new implanters from their first
procedure.
Study limitations
This study has several limitations. First, this is a retrospective cohort
analysis that can only establish associations and not determine caus-
ation. Implant experience may, therefore, be a surrogate marker for
an unidentified confounder. Other confounders that may influence
the learning curve for individual implanters such as differences in
transvenous ICD implant experience/volume or the number of im-
plants that were performed in the presence of a proctor were not
part of the current analysis.
Conclusions
There is a short and significant learning curve associated with phy-
sicians adopting the S-ICD. The complication rate of 9.8% decreased
with increasing experience of individual implanters and stabilized
after 13 implants per implanter at 5.4%. The reduction of IASs and
procedure time likely reflects a global learning effect.
Supplementary material
Supplementary material is available at Europace online.
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